JP2024537804A5 - - Google Patents

Info

Publication number
JP2024537804A5
JP2024537804A5 JP2024519649A JP2024519649A JP2024537804A5 JP 2024537804 A5 JP2024537804 A5 JP 2024537804A5 JP 2024519649 A JP2024519649 A JP 2024519649A JP 2024519649 A JP2024519649 A JP 2024519649A JP 2024537804 A5 JP2024537804 A5 JP 2024537804A5
Authority
JP
Japan
Prior art keywords
antigen
binding polypeptide
chain variable
variable region
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537804A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077200 external-priority patent/WO2023056312A1/en
Publication of JP2024537804A publication Critical patent/JP2024537804A/ja
Publication of JP2024537804A5 publication Critical patent/JP2024537804A5/ja
Pending legal-status Critical Current

Links

JP2024519649A 2021-09-29 2022-09-28 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びそれを使用する方法 Pending JP2024537804A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202163249794P 2021-09-29 2021-09-29
US202163249833P 2021-09-29 2021-09-29
US202163249722P 2021-09-29 2021-09-29
US202163249919P 2021-09-29 2021-09-29
US63/249,919 2021-09-29
US63/249,722 2021-09-29
US63/249,833 2021-09-29
US63/249,794 2021-09-29
US202163291305P 2021-12-17 2021-12-17
US63/291,305 2021-12-17
US202163292382P 2021-12-21 2021-12-21
US63/292,382 2021-12-21
PCT/US2022/077200 WO2023056312A1 (en) 2021-09-29 2022-09-28 Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024537804A JP2024537804A (ja) 2024-10-16
JP2024537804A5 true JP2024537804A5 (cg-RX-API-DMAC7.html) 2025-12-24

Family

ID=85783604

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2024519649A Pending JP2024537804A (ja) 2021-09-29 2022-09-28 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びそれを使用する方法
JP2024519823A Pending JP2024537828A (ja) 2021-09-29 2022-09-28 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びそれを使用する方法
JP2024519821A Pending JP2024537826A (ja) 2021-09-29 2022-09-28 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びそれらを使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024519823A Pending JP2024537828A (ja) 2021-09-29 2022-09-28 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びそれを使用する方法
JP2024519821A Pending JP2024537826A (ja) 2021-09-29 2022-09-28 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びそれらを使用する方法

Country Status (11)

Country Link
US (3) US12668645B2 (cg-RX-API-DMAC7.html)
EP (3) EP4408882A4 (cg-RX-API-DMAC7.html)
JP (3) JP2024537804A (cg-RX-API-DMAC7.html)
KR (3) KR20240099223A9 (cg-RX-API-DMAC7.html)
AU (3) AU2022356387A1 (cg-RX-API-DMAC7.html)
CA (3) CA3232364A1 (cg-RX-API-DMAC7.html)
CL (3) CL2024000898A1 (cg-RX-API-DMAC7.html)
IL (3) IL311765A (cg-RX-API-DMAC7.html)
MX (2) MX2024003808A (cg-RX-API-DMAC7.html)
TW (3) TW202330594A (cg-RX-API-DMAC7.html)
WO (3) WO2023056312A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118317979A (zh) * 2021-09-29 2024-07-09 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
AU2023301087A1 (en) * 2022-06-30 2025-02-13 Modex Therapeutics, Inc. Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
CN122319165A (zh) * 2023-10-03 2026-06-30 瑞沃普斯医疗公司 多特异性抗原结合多肽的组合物和使用方法
US20250326823A1 (en) * 2024-04-03 2025-10-23 Modex Therapeutics, Inc. Antigen Binding Polypeptides, Polypeptide Complexes and Methods of Use Thereof
CN119775368B (zh) * 2024-12-06 2025-11-07 扬州大学 基于gE蛋白保守的B细胞表位肽及其在猪伪狂犬病病毒抗体诊断中的应用
CN120399043B (zh) * 2025-04-17 2026-01-27 唯泰科生物科技(武汉)有限公司 抗猪伪狂犬病毒糖蛋白gB的抗体及其应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE346866T1 (de) 2001-09-14 2006-12-15 Affimed Therapeutics Ag Multimerische, einzelkettige, tandem-fv- antikörper
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
KR101374454B1 (ko) * 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP2522727A1 (en) 2006-03-23 2012-11-14 Tohoku University Highly functional bispecific antibody
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
WO2010109924A1 (ja) 2009-03-25 2010-09-30 国立大学法人東北大学 Lh型二重特異性抗体
WO2011091435A2 (en) * 2010-01-25 2011-07-28 Mount Sinai School Of Medicine Methods of treating liver disease
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JP6407726B2 (ja) 2012-03-01 2018-10-24 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH 長寿命ポリペプチド結合分子
SG10201704846VA (en) 2012-03-14 2017-07-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
EP2938637A2 (en) * 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
US9458244B2 (en) * 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US20140322236A1 (en) * 2013-03-15 2014-10-30 Sdix, Llc Anti-human adora2a antibodies
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
WO2015048272A1 (en) 2013-09-25 2015-04-02 Amgen Inc. V-c-fc-v-c antibody
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
EP3092250A4 (en) * 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2015173756A2 (en) 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
EP3197916A2 (en) 2014-09-25 2017-08-02 Amgen Inc. Protease-activatable bispecific proteins
MX2017012805A (es) 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
ES2984656T3 (es) 2015-05-13 2024-10-30 Ablynx Nv Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108290958B (zh) 2015-10-02 2021-12-28 豪夫迈·罗氏有限公司 多特异性抗体
EP3156417A1 (en) 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
ES2894304T3 (es) * 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
WO2018075564A1 (en) * 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
WO2018158349A1 (en) 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement
KR20200014379A (ko) 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
CN111788225B (zh) 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
WO2019175368A1 (en) 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
WO2019179627A1 (en) * 2018-03-22 2019-09-26 Universität Stuttgart Multivalent binding molecules
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
EP3774914A2 (en) 2018-04-13 2021-02-17 Affimed GmbH Nk cell engaging antibody fusion constructs
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
IL279063B2 (en) * 2018-05-31 2026-05-01 Washington University St Louis Chimeric antigen receptor T cells for cancer treatment
JP7599205B2 (ja) 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
TWI856979B (zh) 2018-10-09 2024-10-01 法商賽諾菲公司 三特異性抗cd38、抗cd28和抗cd3結合蛋白和用於治療病毒感染的使用方法
US12365722B2 (en) 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
EP4578507A3 (en) * 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
TW202104274A (zh) 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療hiv感染之三特異性及/或三價結合蛋白
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
JP7664175B2 (ja) 2019-04-09 2025-04-17 サノフイ 三重特異性結合性タンパク質、方法、およびその使用
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
US20220396635A1 (en) * 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
WO2021089748A2 (en) 2019-11-06 2021-05-14 Amgen Research (Munich) Gmbh Multitargeting antigen-binding molecules for use in proliferative diseases
EP4408892A4 (en) 2021-09-29 2025-11-19 Modex Therapeutics Inc Antigen-binding polypeptides, antigen-binding polypeptide complexes, and their methods of use in HIV
CN118317979A (zh) 2021-09-29 2024-07-09 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118613504A (zh) 2021-12-17 2024-09-06 摩德斯医疗股份有限公司 含有tnfsf配体的细胞外结构域的抗原结合多肽复合物
CN119836434A (zh) 2022-06-30 2025-04-15 摩德斯医疗股份有限公司 抗SARS-CoV-2抗原结合多肽、多肽复合物及其使用方法
AU2023301087A1 (en) 2022-06-30 2025-02-13 Modex Therapeutics, Inc. Anti-sars-cov-2 antigen binding polypeptides, polypeptide complexes and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2024537826A5 (cg-RX-API-DMAC7.html)
JP2024537828A5 (cg-RX-API-DMAC7.html)
CA3232364A1 (en) Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
US12540185B2 (en) Fabs-in-tandem immunoglobulin and uses thereof
TWI788286B (zh) 三特異性和/或三價結合蛋白
JP2022512649A5 (cg-RX-API-DMAC7.html)
JP2019522459A5 (cg-RX-API-DMAC7.html)
AU2012236603A1 (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
JP2025503480A5 (cg-RX-API-DMAC7.html)
JP2025500918A5 (cg-RX-API-DMAC7.html)
JP2024537827A5 (cg-RX-API-DMAC7.html)
ES2960329T3 (es) Proteínas de unión triespecíficas y/o trivalentes
WO2022184659A1 (en) Antibody domains & multimers
CA3011746C (en) Fabs-in-tandem immunoglobulin and uses thereof
RU2023128356A (ru) Антитела к cd38 и комбинации с антителами к cd3 и сd28